



Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department

Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

Activity Description

Immune checkpoint inhibitors represent a major advance in oncology and have shown remarkable benefit in treating a range of cancer types. These agents work by blocking intrinsic downregulators of immunity—the immune checkpoints. As a result, the “brakes” on the immune system are released and T cells are able to attack and kill cancer cells. However, a range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) can also occur as a result of immune activation caused by the immune checkpoint inhibitors. Any organ system can be affected, and the presentation can vary from mild to severe. Timely recognition and effective management of these irAEs is essential to ensure that patients with cancer derive the maximum benefit from the anti-tumor efficacy of these agents. Increasingly, emergency medicine (EM) professionals can expect to encounter higher numbers of acutely unwell patients with irAEs induced by the immune checkpoint inhibitors and combinations.

This curriculum is designed to help you navigate the new challenges at the intersection of EM and immuno-oncology. Need-to-know foundational guidance will be combined with a discussion of real cases. After viewing the onDemand, you can request a meeting at your chapter to have one of our experts visit your institution for an interactive discussion. Change your practice by learning how to recognize, diagnose, and manage irAEs in the emergency department!

Educational Objectives

Upon completion of this activity, participants will be able to:

- Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology
- Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies
- Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED)
- Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED
- Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

Target Audience

This activity has been designed to meet the educational needs of emergency medical physicians, nurses, and other clinicians involved in the management of patients with immune-related adverse events.

Requirements for Successful Completion

In order to receive credit, participants must attend the live activity and complete the evaluation and request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/CNE credit. Statements of Credit are awarded upon completion of the evaluation and request for credit at the end of the post-test and evaluation form.

*Please note that if you are requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number & DOB (MM/DD). A score of 70% or higher is needed to obtain MOC credit.

**For nurses, in order to receive a CNE Statement of Credit, answers to all post-test questions are also required. A score of 70% or higher is needed to obtain CNE credit.

Disclosure and Conflict of Interest Policy

The Medical Learning Institute, Inc. (MLI) requires faculty, planners, staff, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they, and their spouse/life partners, may have as related to the content of this activity. These disclosures will be provided to learners prior to the start of the activity. All identified COI are thoroughly vetted and resolved according to MLI policy. MLI is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Co-Chairs

Evan J. Lipson, MD

Associate Professor, Medical Oncology
Melanoma and Cancer Immunology Programs
Bloomberg–Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Baltimore, Maryland

Evan J. Lipson, MD, has a financial interest/relationship or affiliation in the form of: *Grant/Research Support* from Bristol-Myers Squibb; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Sysmex. All research funding goes to institution. *Consultant and/or Advisor* for Array BioPharma; Bristol-Myers Squibb; EMD Serono, Inc.; MacroGenics, Inc.; Merck & Co., Inc.; and Millennium.

Andrew Stolbach, MD, MPH

Medical Toxicologist
Emergency Physician
Associate Professor, Department of Emergency Medicine
Johns Hopkins Hospital
Johns Hopkins University School of Medicine
Baltimore, Maryland

Andrew Stolbach, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.



PeerView
Live

This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca.



Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department

Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

Planning Committee Disclosures

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Matthew A. Goodman, MD


Gina D. Cravey, BSN, RN, CHRC, CCRC

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME's Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Continuing Nursing Education

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

onDemand Multimedia Activity

If you have not done so already, please visit our website at [PeerView.com/irAE-ED](https://www.peerview.com/irAE-ED), where you'll be able to view the presentation in its entirety and download the program Practice Aids.



PeerView
Live

This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca.